What will value-based drug pricing look like by 2030?

The latest stories trending on MedCity News.

MedCity News' daily newsletter will be paused on February 20 in observance of President's Day. The newsletter will resume on February 21.

Editor's Pick

Top Story What Will Value-Based Drug Pricing Look Like By 2030? Experts Share 4 Predictions Panelists at a recent pharmacy conference were optimistic about the future of value-based drug contracting. For example, one said that healthcare will be close to establishing a value-based formulary by 2030, and another said that longitudinal patient tracking will become a more important part the drug pricing process. Startups Get in Front of These Investors - Here's How: Sofia Guerra, Investor, Bessemer Venture Partners and Harry Glorikian, General Partner, Scientia Ventures   There is no fee to apply. Only companies funded from 2018-2022, and that have raised a seed funding round will be considered. Startups can apply to only one track. There are five tracks and each track will feature six finalists. Application Deadline: February 28, 2023. Selections will be announced on March 22, 2023.   Apply Now

Featured News

Apellis Drug Becomes First Approved Therapy for Vision-Loss Disorder Geographic Atrophy The FDA approved Apellis Pharmaceuticals' Syfovre as a treatment for geographic atrophy, a retinal disorder that is a leading cause of blindness. The drug, administered as an injection into the eye, will launch in March at the price of $2,190 per vial. PBMs Come Under Fire During Senate Hearing The Senate Commerce Committee held a hearing Thursday, which discussed how the Pharmacy Benefit Manager Transparency Act would affect practices by pharmacy benefit managers, including clawbacks. Some questioned why PBMs are even necessary. Decline of Telehealth During the Pandemic and After Telehealth has been an essential tool during the pandemic but recent data shows that its utilization is decreasing as we move into 2021 and beyond. This decrease could lead to increased costs and decreased efficiency for healthcare systems as well as decreased access and poorer health outcomes for patients if nothing is done about it soon. Chiesi Wins FDA Approval for First Drug to Treat Ultra-Rare Enzyme Deficiency Chiesi drug Lamzede is an engineered version of an enzyme that's lacking in patients with the rare disease alpha-mannosidosis. FDA approval of the Chiesi drug comes about five years after European regulators authorized the product. The Adderall Shortage The increased demand for stimulant medications such as Adderall for ADHD is not the result of abuse or misdiagnosis but is caused by a previously unmet need for treatment of ADHD, which telepsychiatry finally satisfied.

Resources

How a Top Health Plan Used AI to Achieve a 34% Increase in Cost Savings In this complimentary eBook you will learn how member outreach has been reimagined with AI-powered care management solutions.   Download Now

MedCity News • 611 Broadway • New York, NY unsubscribe